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PET of EGFR with 64Cu-cetuximab-F(ab′)2 in
mice with head and neck squamous cell
carcinoma xenografts
Laura K. van Dijka,b*, Cheng-Bin Yimc, Gerben M. Franssenb,
Johannes H. A. M. Kaandersa, Johan Rajanderd, Olof Solinc,d,
Tove J. Grönroose, Otto C. Boermanb and Johan Bussinka
Overexpression of the epidermal growth factor receptor (EGFR) is linked to an adverse outcome in various solid
tumors. Cetuximab is an EGFR inhibitor, which in combination with radiotherapy improves locoregional control
and survival in a subgroup of patients with head and neck squamous cell carcinomas (HNSCCs). The aim of this study
was to develop and characterize an EGFR-directed PET tracer, 64Cu-cetuximab-F(ab′)2, to determine the systemic
accessibility of EGFR. Mice with HNSCC xenografts, UT-SCC-8 (n=6) or UT-SCC-45 (n=6), were imaged 24h post
injection with 64Cu-NODAGA-cetuximab-F(ab′)2 using PET/CT. One mouse for each tumor model was co-injected with
excess unlabeled cetuximab 3days before radiotracer injection to determine non-EGFR-mediated uptake. Ex vivo
biodistribution of the tracer was determined and tumors were analyzed by autoradiography and immunohisto-
chemistry. The SUVmax of UT-SCC-8 tumors was higher than that of UT-SCC-45: 1.5 ± 1.0 and 0.8 ± 0.2 (p<0.05),
respectively. SUVmax after in vivo blocking of EGFR with cetuximab was 0.4. Immunohistochemistry showed that
UT-SCC-8 had a signiﬁcantly higher EGFR expression than UT-SCC-45: 0.50 ± 0.19 versus 0.12 ± 0.08 (p< 0.005),
respectively. Autoradiography indicated that 64Cu-cetuximab-F(ab′)2 uptake correlated with EGFR expression in
both tumors: r= 0.86 ± 0.06 (UT-SCC-8) and 0.90 ± 0.06 (UT-SCC-45). 64Cu-cetuxmab-F(ab′)2 is a promising PET
tracer to determine expression of EGFR in vivo. Clinically, this tracer has the potential to be used to determine
cetuximab targeting of tumors and possibly to non-invasively monitor the response to EGFR-inhibitor treatment.
Copyright © 2015 John Wiley & Sons, Ltd.
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1. INTRODUCTION
The epidermal growth factor receptor (EGFR) is a transmem-
branous protein linked to many regulatory cellular pathways.
Its overexpression and activation can have signiﬁcant effects
on cellular processes and are observed in many cancers (1,2).
Anti-EGFR antibodies have shown clinical activity in a variety of
solid tumors including head and neck, colon, non-small-cell lung
and renal cell carcinomas, thereby affecting signaling pathways
leading to cell cycle arrest, apoptosis and inhibition of angiogen-
esis and metastasis formation (3). The EGFR is overexpressed in
80–100% of head and neck squamous cell carcinomas (HNSCCs),
and the monoclonal antibody cetuximab when combined with
radiotherapy has proven to be clinically effective in a small sub-
population of HNSCC patients (4,5). In order to progress to indi-
vidualized treatment and reduce treatment-related toxicity,
patient selection is of major clinical relevance. A well-known
method for patient selection is the immunohistochemical detec-
tion of EGFR expression in biopsy-derived sections of HNSCC
(6,7). However, uncertainties such as biopsy accuracy and tumor
heterogeneity affect the speciﬁcity and reliability of the proce-
dure, and results showed prognostic value but not predictive
value (8). In the last decades, molecular imaging has played an
important role as a noninvasive technique for patient selection,
monitoring and prediction of outcome. EGFR-targeted
biomarkers have been widely investigated; cetuximab and its an-
alogues have been labeled with several radionuclides, including
111In for single photon emission tomography (SPECT) and 124I,
66Ga, 89Zr and86Y for positron emission tomography (PET) (9).
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While whole antibodies accumulate efﬁciently in the tumor, it re-
quires 4–7 days before non-target radioactivity has reached suf-
ﬁciently low levels to enable acquisition of high contrast SPECT
images (10). Conversely, F(ab′)2 fragments demonstrate high
tumor-to-background signal ratios at earlier time points, while
retaining tumor-binding characteristics similar to those of whole
antibodies (11,12). Previous in vivo studies have shown that
111In-cetuximab-F(ab′)2 can visualize EGFR accessibility in mice. It
displayed a differential uptake in head and neck xenografts, with
varying levels of EGFR expression and differential response to
treatment with radiotherapy and/or cetuximab (13–15). The aim
of this study is to develop a PET-based imaging agent with clinical
perspective for imaging EGFR, as PET has a higher resolution and
allows more accurate quantitative analyses of images than SPECT
(16). The decay properties of 64Cu include an intermediate half-life
of 12.7 h, which is equal to the circulatory half-life of F(ab′)2 frag-
ments. Its low positron emission energy (Emax = 0.65MeV) provides
high spatial resolution for PET and autoradiography (17). There-
fore, the combination of PET, cetuximab-F(ab′)2 and
64Cu creates
certain potential for the clinical imaging of EGFR.
2. MATERIALS AND METHODS
2.1. Synthesis and radiochemistry
Cetuximab-F(ab′)2 was produced as described previously and
puriﬁed by gel ﬁltration chromatography on a G25M Sephadex col-
umn (14). Cetuximab-F(ab′)2 was conjugatedwith 2,2′-(7-(1-carboxy-
4-((4-isothiocyanatobenzyl)amino)-4-oxobutyl)-1,4,7-triazonane-1,4-
diyl)diacetic acid (ITC-NODAGA) (CheMatech, Dijon, France) in 0.1M
NaHCO3, pH9.5, for 3 h at room temperature using a 20-fold molar
excess of ITC-NODAGA. Unbound ITC-NODAGAwas removed by di-
alysis against NH4OAc (0.25M, pH5.5).
64Cu (t½=12.7 h, β
+ = 17%, β= 39%, EC = 44%) in the form of
(64Cu)CuCl2 was produced via the
64Ni(p, n)64Cu nuclear reaction,
as described previously (18,19). 64Cu was formulated as
5MBq/μL in 0.04M HCl solution. The antibody fragments (1μg)
were labeled with 64Cu (5MBq, 1μL) in 25μL of 2-(N-
morpholino)ethanesulfonic acid (MES) buffer, pH 5.5 at room
temperature. After 30min, labeling efﬁciency was determined
using instant thin-layer chromatography (ITLC) on TEC Control
chromatography strips (Biodex, Shirley, NY, USA), with 0.1M cit-
rate buffer, pH 6.0, as the mobile phase. Radiochemical purity
of 64Cu-cetuximab exceeded 98% in all preparations. The speciﬁc
activity of the tracer was 500GBq/μmol.
2.2. In vitro characterization
64Cu-cetuximab-F(ab′)2 (1.2MBq, 10μL) was added to 100μL of
murine plasma to assess stability. The mixture was incubated at
37°C. After 4 and 26 h incubation, aliquots of 1μL were analyzed
by ITLC (0.1M citrate buffer, pH 6.0).
2.3. Tumor models
Human HNSCC UT-SCC-8 or UT-SCC-45 xenografts (1mm3,
1 × 106 cells) were injected in the right hind leg of male athymic
BALB/c nu/nu mice (6–10 weeks). UT-SCC-8 originated from a
supraglottic larynx and UT-SCC-45 from a primary cancer of the
ﬂoor of the mouth (University of Turku). Animals were housed
in ﬁlter-topped cages in a speciﬁc-pathogen-free unit in
accordance with institutional guidelines. Experiments started
48 days (UT-SCC-8) or 41 days (UT-SCC-45) after transplantation.
Tumor volume was estimated using the formula (4/3)πr1r2r3. At
the start of the experiment, the mean size of the tumors was
764 cm3, with a standard error of 150 cm3. The experiment pro-
cedures were reviewed by the Ethics Committee on Animal
Experimentation of the University of Turku and approved by
the Provincial State Ofﬁce of Western Finland.
2.4. Biodistribution and PET/CT studies
64Cu-cetuximab-F(ab′)2 (21 ± 2.6MBq, 15μg, 250μL) was intrave-
nously injected in the tail vein followed by 100μL of 0.9% NaCl
to ﬂush the catheter. One additional mouse of each tumor model
was injected with an excess dose of unlabeled cetuximab (1mg)
3 days prior to tracer injection. Saturation of the antigen is often
achieved by co-injection; however, as cetuximab F(ab′)2 targets
the tumormuch faster than cetuximab IgG, injectionwith unlabeled
antibody is administered 3days before F(ab′)2 tracer injection. Mice
were anesthetizedwith 2.5% isoﬂurane and positioned in an Inveon
PET/CT scanner (Siemens Medical Solutions, Knoxville, TN, USA) for
an 8min CT acquisition and 30min PET scan in list mode, with an
energy window of 350–650 keV. The PET scanner had an axial ﬁeld
of view of 12.7 cm and a spatial resolution of 1.4mm full width at
half-maximum. During scans, the body temperature of the mice
was kept at 37°C with a heating pad on the scanner bed.
Subsequently, mice were euthanized and the biodistribution of
the radiolabel at 24h p.i. was determined.
2.5. Immunohistochemistry and autoradiography
Frozen tumor sections (5μm) were cut and mounted on
poly-L-lysine-coated slides for autoradiography. Slides were
exposed to an imaging plate (BAS-TR2025, Fuji Photo Film,
Tokyo, Japan) for three days. The imaging plates were
scanned using a Fuji BAS-5000 analyzer at a pixel size of
25 × 25μm2. Images were processed using a computerized
image analysis program (Aida Image Analyzer software 4.19,
Raytest Isotopenmessgeräte, Staubenhardt, Germany).
After autoradiography, the same slides were stained
immunohistochemically. Tumor sections were ﬁxed in acetone at
4°C for 10min. Subsequently, sections were rehydrated in
phosphate-buffered saline (PBS) and stained for EGFR. Primary
and secondary antibodies were diluted in primary antibody diluent
(Abcam, Cambridge, UK). Between all consecutive steps of the
staining process, sections were rinsed three times each for 5min
in 0.1M PBS, pH7.4 (Klinipath, Duiven, The Netherlands). After
rehydration in PBS, sections were incubated with goat anti-EGFR
antibody 1:50 (Santa Cruz Biotechnology, Dallas, Texas, USA) and
subsequently with donkey anti-goat Cy3, 1:600 (Jackson
ImmunoResearch, West Grove, PA, USA), after which slides were
mounted in Fluorostab (ICN, Basingstoke, UK).
2.6. Image analysis
PET images were reconstructed using an OSEM 3D algorithm of
two iterations followed by maximum a posteriori (MAP, 18 itera-
tions) integrative algorithms (Inveon Acquisition Workplace, ver-
sion 1.5, Siemens Preclinical Solutions).
Reconstructed images were analyzed with Siemens Inveon
Research Workplace software (version 4.0, Siemens Preclinical
Solutions) by manually placing regions of interest (ROIs) around
the tumor. Quantiﬁcation of tracer uptake in tumor ROIs of the
attenuation-corrected slices was obtained by calculating the
maximum standardized uptake values (SUVmax) by correcting
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for the injected activity, injection time (decay) and bodyweight.
SUVmax was chosen as it is more reproducible than SUVmean,
since the maximum value within an ROI is typically less depen-
dent on ROI position with respect to small spatial shifts.
Immunohistochemically stained tumor sections were ana-
lyzed using a digital image analysis system, as described pre-
viously (20). In short, whole-tissue sections were scanned
(magniﬁcation × 10, Axioskop, Zeiss, Göttingen, Germany)
and gray-scale images (pixel size, 2.59 × 2.59 μm2) were
obtained for vessels, EGFR and nuclei, and subsequently
converted into binary images. Using ImageJ software (version
1.43m, JAVA-based image-processing package), the number
of positive pixels for EGFR staining (fEGFR) was divided by
total tumor area. Thresholds for segmentation of the ﬂuores-
cent signals were set above the background staining for each
marker. Areas of necrosis were excluded from analysis by
drawing ROIs.
Colocalization analysis was performed on autoradiography
and immunohistochemical gray-value images (grayscale range
0–255). Images were overlaid using Photoshop (CS4, version
11.0.2, San Jose, CA, USA), and the pixel and ﬁgure size of the
immunohistochemistry images was rescaled to match that of
the autoradiography images for alignment (25 × 25 μm2) and
was successively upscaled (100 × 100 μm2) to compensate for
image co-registration errors and scattering of the tracer sig-
nal in the autoradiography images. After alignment, ROIs
drawn previously for excluding necrosis in immunohisto-
chemical analysis were masked in autoradiography images.
Co-registered pixel gray-values and overlap coefﬁcients were
determined with ImageJ using the JACoP plugin package
(21). Positioning accuracy between the autoradiography
and immunohistochemistry images, as reported by the over-
lap coefﬁcient calculated with the ImageJ JACoP plugin, was
over 95%.
2.7. Statistics
Statistical analyses were performed using Prism software version
6.0 (GraphPad, San Diego, CA, USA). Signiﬁcance was tested with
the non-parametric Mann–Whitney test and/or repeated mea-
sures ANOVA. The non-parametric Spearman or parametric Pear-
son test was used accordingly, and a p-value ≤ 0.05 was
considered signiﬁcant. Data values are represented as mean
± standard deviation.
3. RESULTS
3.1. In vitro characterization
64Cu-cetuximab-F(ab′)2 was moderately stable in murine plasma.
After 2 h and 26 h incubation at 37°C, 90% and 84% respectively
of the radioactivity was still associated with the intact
radiotracer.
3.2. Biodistribution
At 24 h p.i., the tumor biodistribution of 64Cu-cetuximab-F(ab′)2
in the UT-SCC-8 and UT-SCC-45 xenografts was similar: 5.48
± 1.29% ID/g and 4.23 ± 2.06% ID/g, respectively (p= 0.36). Mice
that were pre-injected with an excess of unlabeled cetuximab
had lower tumor uptake: 0.82% ID/g for UT-SCC-8 and 0.81%
ID/g for UT-SCC-45. The biodistribution of 64Cu-cetuximab-F(ab′)2
in mice with HNSCC xenografts is summarized in Fig. 1. At
24 h p.i., tumor-to-blood ratios in the two models were similar:
12.8± 5.2 for UT-SCC-8 and 10.6± 4.6 for UT-SCC-45 (p=0.53).
The kidneys and the liver were the normal tissues with the
highest uptake: 7.9± 1.2% ID/g and 8.0± 0.7% ID/g for UT-SCC-8;
6.7 ± 3.9% ID/g and 9.0± 0.5% ID/g for UT-SCC-45, respectively.
3.3. PET studies
Images showed a higher64Cu-cetuximab-F(ab′)2 uptake in UT-
SCC-8 tumors than in UT-SCC-45 tumors (Fig. 2). The SUVmax dif-
fered signiﬁcantly: 1.5 ± 1.0 for UT-SCC-8 and 0.8 ± 0.2 for UT-
SCC-45 (p< 0.05) (Fig. 3). SUVmax values of the tumors of the
mice pre-injected with excess unlabeled cetuximab were clearly
lower: SUVmax was 0.4 for both UT-SCC-8 and UT-SCC-45.
3.4. Immunohistochemistry and autoradiography
UT-SCC-8 had a signiﬁcantly higher expression of EGFR com-
pared with UT-SCC-45: the receptor-positive fraction was 0.50
± 0.19 versus 0.12 ± 0.08 (p< 0.005), respectively (Fig. 4). Autora-
diography images of 64Cu-cetuximab-F(ab′)2 correlated with spa-
tial EGFR expression as determined immunohistochemically for
both tumor lines: the correlation coefﬁcient (r) was 0.86 ± 0.06
for UT-SCC-8 and 0.90 ± 0.06 for UT-SCC-45 (Fig. 5). The tumor
from one mouse was omitted from the analysis owing to inability
to align after skewing of the slide.
4. DISCUSSION
The present study shows that 64Cu-cetuximab-F(ab′)2 can be
used as a tracer to determine EGFR expression in HNSCCs nonin-
vasively with PET. A signiﬁcant correlation was found between
the intratumoral localization of 64Cu-cetuximab-F(ab′)2 as deter-
mined by autoradiography and EGFR expression as determined
immunohistochemically, indicating that the EGFR expressed on
the tumor cells is speciﬁcally targeted by the tracer.
Accumulation of 64Cu-cetuximab-F(ab′)2 in the tumor was
EGFR mediated in both UT-SCC-8 and UT-SCC-45, as it could be
inhibited by pre-injection of an excess of unlabeled cetuximab.
Tumor uptake of 64Cu-cetuximab-F(ab′)2 in terms of % ID/g was
similar to that of the 111In-labeled cetuximab-F(ab′)2 tracer as de-
scribed previously (13–15). Cetuximab has been radiolabeled
with 64Cu in several other studies, using DOTA as a chelator
(22–27). However, this resulted in increased radioactivity levels
Figure 1. Biodistribution of 64Cu-cetuximab-F(ab′)2. Black bars, mice
with UT-SCC-8 (n = 5); white bars, mice with UT-SCC-45 (n = 5) tumors,
24 h p.i. Tissue uptake values are presented as percentages of injected
dose per gram of tissue and expressed as mean ± SD.
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in the liver, which was attributed to transchelation of Cu2+ from
DOTA to superoxide dismutase and ceruloplasmin (28). Previous
reports have demonstrated the enhanced thermodynamic
stability of Cu-triazamacrocyclic complexes compared with Cu-
DOTA derivatives (29–35).
Yaromina et al. determined the TCD50 of these UT-SCC tumors,
i.e. the dose necessary to locally control 50% of the tumors, and
showed that the radiosensitivities of UT-SCC-8 and UT-SCC-45
were similar, with TCD50 values of 53Gy and 45Gy, respectively
(36). PET images and SUVmax quantiﬁcation showed a signiﬁcant
difference in 64Cu-cetuximab-F(ab′)2 uptake between the two
HNSCC tumors, which might reﬂect the sensitivity of these tu-
mors towards EGFR inhibitors. The 64Cu-cetuximab-F(ab′)2 tumor
uptake of UT-SCC-45 was lower, which suggests that this tumor
might not beneﬁt from EGFR-targeted therapy, while the tumor
with higher tracer uptake, UT-SCC-8, might be more sensitive
to EGFR inhibition. However, more HNSCC tumor models should
be analyzed to validate whether tracer uptake correlates with
sensitivity to cetuximab treatment.
Some discrepancy was noted between PET-derived SUVmax
and ex vivo biodistribution data, the latter showing no signiﬁcant
difference of tracer uptake in the two HNSCC tumors. The lack of
a signiﬁcant difference in tumor uptake could be due to necrotic
areas in both UT-SCC tumor lines, thereby increasing the appar-
ent tumor weight and distorting the uptake per gram tumor tis-
sue, but having no effect on the SUVmax, as necrotic areas with
low uptake are excluded from that analysis.
In a previous study, 111In-cetuximab-F(ab′)2 has been shown to
be able to measure radiation-induced changes of EGFR expres-
sion. Irradiated SCCNij202 tumors exhibited an increase in
111In-cetuximab-F(ab′)2 uptake up to 14 days after treatment,
which correlated with an increase of available membranous
EGFR as determined immunohistochemically (15). Intratumoral
localization of EGFR in HNSCCs is heterogeneous, and to allow
accurate tracer quantiﬁcation and reduction of partial volume
effects it is necessary to acquire high-resolution images. Clinical
PET images have a better spatial resolution than SPECT images
(2–5mm versus 7–10mm), encouraging the development of
PET tracers for this application (16). The ability of 64Cu-
cetuximab-F(ab′)2 to monitor treatment has not yet been
established, but the current study shows that this PET tracer is
able to accurately measure heterogeneous EGFR expression in
tumors within a relatively short time period.
Optimization of kinetics and speciﬁcity of PET tracers is neces-
sary in order to advance in a clinical setting. Longitudinal
Figure 3. SUVmax of
64Cu-cetuximab-F(ab′)2 in UT-SCC tumors.
64Cu-
cetuximab-F(ab′)2 in UT-SCC-8 (n = 5, grey bar) and UT-SCC-45 (n = 5,
white bar) from PET imaging 24 h after injection. One mouse per tumor
model received an excess unlabeled dose of 1mg cetuximab 3 days prior
to tracer injection (block). Data are presented as mean ± SD.* p< 0.05.
Figure 4. The immunohistochemical EGFR fraction of UT-SCC tumors.
The immunohistochemical fraction of EGFR (fEGFR) of UT-SCC-8 (n = 5,
grey bar) and UT-SCC-45 tumors (n = 5, white bar). UT-SCC-8 tumors
had a signiﬁcantly increased fEGFR (p< 0.01). Mean ± SD.
Figure 2. PET/CT images of 64Cu-cetuximab-F(ab′)2 in mice with UT-SCC tumors. Typical examples of PET/CT images of
64Cu-cetuximab-F(ab′)2 distri-
bution in mice with subcutaneous UT-SCC-8 (a, b) or UT-SCC45 (c, d) tumors. b and d were pre-injected with excess cetuximab. Tumors are located
subcutaneously on the right hind leg (arrow). Background uptake visible in PET images is liver, kidneys and bladder. Scans were conducted 24 h p.i.
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measurement of EGFR expression could elucidate patient-
speciﬁc tumor characteristics during the course of the disease
and during treatment, thereby facilitating personalized treat-
ment. The preclinical data described here suggest the potential
of 64Cu-cetuximab-F(ab′)2 as a clinical EGFR-targeting tracer.
5. CONCLUSION
This report described the successful NODAGA conjugation and
64Cu labeling of cetuximab-F(ab′)2 with high speciﬁc radioactivity.
PET studies showed the potential of the 64Cu-cetuximab-F(ab′)2
radiotracer to determine systemically targetable EGFR
expression in heterogeneous tumors with superior image
quality at a relatively early time interval. The tracer accumu-
lated rapidly in two different HNSCC tumor models with
good tumor-to-background signal at 24 h after injection. Tracer
uptake in the tumor models studied correlated to EGFR
expression as measured by immunohistochemistry. Imaging
with the PET tracer 64Cu-cetuxmab-F(ab′)2 shows clinical
promise in determining intratumoral EGFR distribution, and
might predict cetuximab accumulation and subsequent
response to EGFR-inhibitor treatment.
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Figure 5. Correlation of EGFR immunohistochemistry and 64Cu-cetuximab-F(ab′)2 autoradiography. (a–d) UT-SCC-8 EGFR immunohistochemistry im-
age (top) and corresponding autoradiography (bottom) (a), immunohistochemistry image of UT-SCC-45 (top) and corresponding autoradiography (bot-
tom) (b) and their respective correlations (c, d). (e) The intratumoral distribution of 64Cu-cetuximab-F(ab′)2 as determined by autoradiography correlated
well with the immunohistochemical distribution of EGFR (r = 0.88, range 0.76–0.97), mean ± SD. Magniﬁcation × 10. Bars: 2000 μm.
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